Edition:
United States

AstraZeneca PLC (AZN.N)

AZN.N on New York Stock Exchange

33.73USD
21 Nov 2017
Change (% chg)

$0.35 (+1.05%)
Prev Close
$33.38
Open
$33.49
Day's High
$33.91
Day's Low
$33.49
Volume
289,366
Avg. Vol
744,663
52-wk High
$35.60
52-wk Low
$25.56

Latest Key Developments (Source: Significant Developments)

Almirall announces achievement of $80 mln sales-related milestones from agreement with Astrazeneca‍​
Friday, 17 Nov 2017 02:38am EST 

Nov 17 (Reuters) - ALMIRALL SA ::ANNOUNCES ACHIEVEMENT OF $80 MILLION SALES-RELATED MILESTONES FROM AGREEMENT WITH ASTRAZENECA‍​.  Full Article

Astrazeneca says U.S. FDA approved fasenra (benralizumab) for severe eosinophilic asthma
Tuesday, 14 Nov 2017 06:38pm EST 

Nov 14 (Reuters) - Astrazeneca Plc :Astrazeneca - co, Medimmune, announced that U.S. FDA approved fasenra (benralizumab) for severe eosinophilic asthma.Astrazeneca - FDA approval based on phase III programme showing up to 51 pct reduction in asthma exacerbations & 75 pct reduction in daily oral steroid use‍​.  Full Article

Astrazeneca says EU approves new indication for Faslodex in combination with palbociclib
Tuesday, 14 Nov 2017 07:24am EST 

Nov 14 (Reuters) - Astrazeneca Plc :FASLODEX (FULVESTRANT) RECEIVES EU APPROVAL FOR THE TREATMENT OF HORMONE RECEPTOR-POSITIVE ADVANCED BREAST CANCER IN COMBINATION WITH PALBOCICLIB1.  Full Article

Astrazeneca says Benralizumab receives Positive EU CHMP opinion
Friday, 10 Nov 2017 06:35am EST 

Nov 10 (Reuters) - ASTRAZENECA PLC ::BENRALIZUMAB POSITIVE CHMP IN EOSINOPHILIC ASTHMA.‍ANNOUNCED THAT CHMP OF EUROPEAN MEDICINES AGENCY HAS ADOPTED POSITIVE OPINION, RECOMMENDING MARKETING AUTHORISATION OF BENRALIZUMAB​.  Full Article

AstraZeneca CEO committed to dividend
Thursday, 9 Nov 2017 07:49am EST 

Nov 9 (Reuters) - AstraZeneca CEO Pascal Soriot says::* committed to dividend "today, tomorrow and day after".  Full Article

AstraZeneca CEO still sees 2023 sales above $40 billion at today's FX
Thursday, 9 Nov 2017 04:43am EST 

Nov 9 (Reuters) - AstraZeneca CEO Pascal Soriot told reporters::working to duplicate quality control systems so can release drugs in EU if hard Brexit.sees high growth rate in China sustainable for next 2-3 years.long term plan confirms we can get to $40-41 billion sales target by 2023 at current exchange rates.  Full Article

‍AstraZeneca Canada says Health Canada has approved Imfinzi for treatment of advanced bladder cancer in previously treated patients​
Monday, 6 Nov 2017 07:59am EST 

Nov 6 (Reuters) - AstraZeneca PLC :‍AstraZeneca Canada says Health Canada has approved Imfinzi for treatment of advanced bladder cancer in previously treated patients​.‍AstraZeneca Canada says Imfinzi has been granted notice of compliance with conditions (noc/c) based on tumour response rate and durability of response​.  Full Article

Astrazeneca provides Tralokinumab update in severe asthma​
Wednesday, 1 Nov 2017 03:00am EDT 

Nov 1 (Reuters) - Astrazeneca Plc ::ASTRAZENECA TRALOKINUMAB UPDATE IN SEVERE ASTHMA​.ANNOUNCED TOP-LINE RESULTS OF PHASE III STRATOS 2, TROPOS TRIALS FOR TRALOKINUMAB.‍IN STRATOS 2, TRALOKINUMAB DID NOT ACHIEVE A STATISTICALLY-SIGNIFICANT REDUCTION IN ANNUAL ASTHMA EXACERBATION RATE (AAER), PRIMARY ENDPOINT.‍IN TROPOS, TRALOKINUMAB DIDN'T ACHIEVE STATISTICALLY-SIGNIFICANT REDUCTION IN ORAL CORTICOSTEROID (OCS) USE, PRIMARY ENDPOINT.‍SAFETY AND TOLERABILITY FINDINGS IN STRATOS 2 AND TROPOS WERE CONSISTENT WITH THOSE OBSERVED IN PREVIOUS TRIALS WITH TRALOKINUMAB​.  Full Article

U.S. FDA grants accelerated approval to Astrazeneca Pharmaceuticals' Calquence ‍​
Tuesday, 31 Oct 2017 02:34pm EDT 

Oct 31 (Reuters) - U.S. Food and Drug Administration::U.S. Food and Drug Administration grants accelerated approval to Astrazeneca Pharmaceuticals LP's Calquence ‍​.  Full Article

Incyte and AstraZeneca to enter clinical trial collaboration in early lung cancer
Tuesday, 31 Oct 2017 03:00am EDT 

Oct 31 (Reuters) - Incyte Corp :Incyte and AstraZeneca to enter clinical trial collaboration in early lung cancer.Incyte - ‍phase 3 trial evaluating Imfinzi and epacadostat in patients with unresectable non-small cell lung cancer is expected to begin in first-half 2018​.  Full Article

Photo

Roche win boosts case for adding chemo to cancer immunotherapy

LONDON Cancer doctors struggling to work out the best way to use modern immunotherapy drugs now have further evidence of the benefits of adding them to chemotherapy, despite earlier scepticism.